Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache

PURPOSE: In a phase 3 study, galcanezumab significantly reduced the frequency of episodic cluster headache attacks across weeks 1–3 (primary endpoint) compared with placebo. However, multiple pain dimensions may contribute to the total burden of episodic cluster headache pain. This post hoc analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrews, J Scott, Kudrow, David, Rettiganti, Mallikarjuna, Oakes, Tina, Bardos, Jennifer N, Wenzel, Richard, Kuruppu, Dulanji K, Gaul, Charly, Martinez, James M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275210/
https://www.ncbi.nlm.nih.gov/pubmed/34267550
http://dx.doi.org/10.2147/JPR.S305066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275210/
https://www.ncbi.nlm.nih.gov/pubmed/34267550
http://dx.doi.org/10.2147/JPR.S305066

Ejemplares similares